Medwise Pharmaceuticals Limited signed a preliminary agreement to acquire Tricel S.A. from BIOTON S.A. (WSE:BIO) for €3.3 million on April 10, 2017. On April 27, 2017, Bioton S.A. and Medwise Pharmaceuticals Limited signed the necessary documentation for the transfer of shares, as well as Tricel S.A.’s debts to Medwise Pharmaceuticals Limited. Under the terms of the transaction, the ownership of the shares will be transferred to Medwise Pharmaceuticals Limited after signing the relevant documents by the parties and after crediting bank account of Bioton S.A. with the price for the shares and for Tricel S.A.’s debts. On April 27, 2017, Bioton S.A.'s bank account was also credited with the amount of €2.5 million leading to the transfer of ownership of titles of the shares and Tricel S.A.'s debts to Medwise Pharmaceuticals Limited. According to the preliminary agreement, a final deal should be signed by June 1, 2017. Termination of the preliminary agreement is possible if Fisiopharma s.r.l. or Pharmatex Italia s.r.l cease their operations or in case of occurrences of significant negative impact on the value of subject matter of the disposal. The transfer of Fisiopharma s.r.l's debt is subject to potential deductions by the amounts of Medwise Pharmaceuticals Limited's claims arising out of Bioton S.A.'s warranties set out in the preliminary agreement upon submission and recognition by Bioton S.A. The completion of the preliminary agreement with the transfer of Fisiopharma s.r.l's debt will be affected on December 31, 2017 at the latest, for the price of €1 million. Medwise Pharmaceuticals Limited completed the acquisition of Tricel S.A. from BIOTON S.A. (WSE:BIO) on December 3, 2017. The deal was concluded after receipt of €1 million by Bioton S.A. in relation to the transfer of Fisopharma s.r.l's debt.